[go: up one dir, main page]

MX2009006476A - Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget. - Google Patents

Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget.

Info

Publication number
MX2009006476A
MX2009006476A MX2009006476A MX2009006476A MX2009006476A MX 2009006476 A MX2009006476 A MX 2009006476A MX 2009006476 A MX2009006476 A MX 2009006476A MX 2009006476 A MX2009006476 A MX 2009006476A MX 2009006476 A MX2009006476 A MX 2009006476A
Authority
MX
Mexico
Prior art keywords
azabicyclo
nonane
osteoporosis
treating
diphosphonic acid
Prior art date
Application number
MX2009006476A
Other languages
English (en)
Inventor
Frank Hallock Ebetino
Robert Kenneth Boeckman Jr
Xinyi Song
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2009006476A publication Critical patent/MX2009006476A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe una nueva composición de materia, ácido(1 R,6S)-2- Azabiciclo-[4.3.O]nonano-8,8-difosfónico sustancialmente, enantioméricamente puro, métodos de preparar esta nueva composición de materia, una composición farmacéutica que comprende la nueva composición, y administración de la composición en métodos para tratar transtomos óseos tales como osteoporosis, metástasis ósea osteolítica, artritis reumatoide y osteoartritis.
MX2009006476A 2006-12-14 2007-12-14 Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget. MX2009006476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87482106P 2006-12-14 2006-12-14
PCT/US2007/025753 WO2008076417A1 (en) 2006-12-14 2007-12-14 (1r,6s)-2-azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or paget's disease

Publications (1)

Publication Number Publication Date
MX2009006476A true MX2009006476A (es) 2009-06-26

Family

ID=39272125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006476A MX2009006476A (es) 2006-12-14 2007-12-14 Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget.

Country Status (8)

Country Link
US (1) US7781418B2 (es)
EP (1) EP2089403B1 (es)
JP (1) JP5282041B2 (es)
CN (1) CN101636404B (es)
CA (1) CA2672191C (es)
ES (1) ES2472705T3 (es)
MX (1) MX2009006476A (es)
WO (1) WO2008076417A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004769A (es) 2009-10-26 2012-08-08 Warner Chilcott Co Llc Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo.
WO2011147038A1 (en) 2010-05-28 2011-12-01 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
GB201305947D0 (en) * 2013-04-02 2013-05-15 Univ Sheffield New method 1
GB201305948D0 (en) * 2013-04-02 2013-05-15 Univ Sheffield New method 2
CN114848656B (zh) 2015-09-09 2024-09-27 清华大学 作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US3988443A (en) 1973-08-27 1976-10-26 Henkel & Cie G.M.B.H. Azacycloalkane-2,2-diphosphonic acids
US4230700A (en) 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4687768A (en) * 1984-12-21 1987-08-18 The Procter & Gamble Company Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4868164A (en) * 1986-12-19 1989-09-19 Norwich Eaton Pharmaceuticals, Inc. Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
CZ296094A3 (en) * 1992-05-29 1995-09-13 Procter & Gamble Pharma Phosphonate compounds containing quaternary nitrogen and intended for treating abnormal metabolism of calcium and phosphates

Also Published As

Publication number Publication date
EP2089403B1 (en) 2014-05-07
JP2010513290A (ja) 2010-04-30
ES2472705T3 (es) 2014-07-02
JP5282041B2 (ja) 2013-09-04
WO2008076417A1 (en) 2008-06-26
CN101636404B (zh) 2014-05-28
EP2089403A1 (en) 2009-08-19
US20090069272A1 (en) 2009-03-12
CN101636404A (zh) 2010-01-27
CA2672191C (en) 2013-05-14
CA2672191A1 (en) 2008-06-26
US7781418B2 (en) 2010-08-24

Similar Documents

Publication Publication Date Title
MX2009006476A (es) Acido (1r,6s)-2-azabiciclo-[4.3.0]nonano-8,8-difosfonico y su uso en el tratamiento o prevencion de trastornos oseos, por ejemplo, osteoporosis o enfermedad de paget.
WO2010131922A3 (en) Amide compound, preparation method thereof and pharmaceutical composition comprising same
WO2011065800A3 (ko) 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
MY140080A (en) Treatment and prevention of osteoporosis
JO2686B1 (en) Vehicles
TN2009000189A1 (en) Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
WO2008041118A3 (en) Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
TW200612892A (en) Novel compounds
MXPA05007792A (es) Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.
UA99818C2 (ru) Лечение заболеваний хряща
WO2008020306A3 (en) Isoindole derivatives
PT1781596E (pt) Pró-fármacos de propofol derivados de aminoácidos, composições e utilizações dos mesmos
TW200639156A (en) New compounds
MY153932A (en) A medicinal product and treatment
SG10201406846XA (en) Bisphosphonate compounds for treating bone metabolism disorders
WO2010033981A3 (en) 5-azaindole bisphosphonates
WO2010033980A3 (en) 4-azaindole bisphosphonates
WO2009148290A3 (en) 3-substituted propanamine compounds
TW200728300A (en) Therapeutic agents
DK1638544T3 (da) Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande
PL1651592T3 (pl) Nowe dibenzo[b,f]oksepino-10-karboksyamidy i ich zastosowania farmaceutyczne
MX2009005804A (es) Composicion farmaceutica de memantina.
ZA200805598B (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration